Kamada Stock Price, News & Analysis

Kamada Ltd (NASDAQ: KMDA; TASE: KMDA.TA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products indicated for rare and serious conditions. According to the company’s public disclosures, Kamada has a portfolio of marketed products, multiple commercial segments, and expanding plasma collection operations that together form the core of its business.

Business focus and therapeutic portfolio

Kamada describes itself as a leader in the specialty plasma-derived therapies field. Its proprietary portfolio includes six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®. In addition, the company markets KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products. These products are indicated for rare and serious conditions and are marketed in multiple countries, with company statements referencing commercial reach in over 30 countries.

Beyond its own brands, Kamada also operates a Distribution segment that commercializes in-licensed third-party biopharmaceutical products. Company releases highlight the launch and growth of biosimilar products in Israel as a key component of this segment, as well as distribution activities in Israel and the MENA region through in-licensing partnerships.

Proprietary products and disease areas

Public information about Kamada’s products indicates activity across several therapeutic areas. GLASSIA® is described as an AAT-IV treatment for Alpha-1 Antitrypsin Deficiency (AATD), marketed internationally, including in the U.S. and Canada through a license agreement with Takeda. CYTOGAM® (CMV-IGIV) is an intravenous immunoglobulin indicated for prophylaxis of cytomegalovirus (CMV) disease associated with transplantation of kidney, lung, liver, pancreas and heart. Company communications also reference anti-rabies immunoglobulin (KAMRAB®) and other specialty immunoglobulins and anti-snake venom products.

In addition to marketed products, Kamada has pursued development programs. Its lead product candidate has been an Inhaled AAT therapy for AATD, evaluated in the pivotal Phase 3 InnovAATe trial. In December 2025, the company reported that, based on a prespecified interim futility analysis, this trial was unlikely to demonstrate a statistically significant benefit in its primary endpoint and would be discontinued, while noting that this decision was not related to safety concerns. Kamada continues to emphasize its commitment to the AATD community through supply of GLASSIA®.

Strategic growth pillars

Across multiple investor and press communications, Kamada outlines a strategy centered on several growth pillars:

• Organic commercial growth from its proprietary specialty plasma-derived products and from its distribution portfolio, including biosimilars in Israel.
• Business development, in-licensing, collaborations and M&A aimed at enhancing its marketed products portfolio and using its existing commercial infrastructure and financial resources to support long-term growth.
• Expansion of plasma collection operations to supply normal source plasma to other plasma-derived manufacturers and to meet Kamada’s own demand for hyper-immune plasma.
• Research and development to advance additional product candidates in areas of significant unmet medical need.

The company reports that FIMI Opportunity Funds, a private equity firm based in Israel, is its controlling shareholder and beneficially owns approximately 38% of Kamada’s outstanding ordinary shares.

Plasma collection and vertical integration

Kamada highlights its growing plasma collection infrastructure as a core operational asset. The company owns three operating plasma collection centers in the United States, located in Beaumont, Houston and San Antonio, Texas. These centers are structured to collect both normal source plasma and specialty plasma, such as anti-rabies and anti-D plasma. The Houston facility, described as a state-of-the-art center, has received U.S. FDA approval to commence commercial sales of normal source plasma and is planned with a substantial annual collection capacity.

By expanding plasma collection capacity, Kamada aims to support sales of normal source plasma to other manufacturers and to supply its own production of hyper-immune plasma-derived therapies. Company statements describe this as part of an effort to strengthen vertical integration, reduce specialty plasma costs and support continued growth.

Geographic and commercial footprint

Kamada identifies itself as a global company with products marketed in over 30 countries. Public announcements reference commercial activities in the U.S., Canada, Israel and additional international markets. For example, the company has reported supplying KAMRAB® and GLASSIA® in Canada, and securing an extension of a supply tender with Canadian Blood Services for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM® and VARIZIG®.

In Israel, Kamada’s Distribution segment focuses on in-licensed products, including biosimilars. The company has also indicated plans to expand its distribution business into the MENA region. These activities complement its proprietary product sales and contribute to the diversity of its revenue base, as described in its financial communications.

Financial profile and segments

Kamada’s public financial reports describe a business composed of at least two main segments: a Proprietary Products segment, which includes specialty plasma-derived therapies and other proprietary products, and a Distribution segment, which covers commercialization of third-party biopharmaceutical products. Company guidance and quarterly updates emphasize revenue growth and adjusted EBITDA as key performance indicators, and management frequently comments on the contribution of product and geographic mix, including increased sales of GLASSIA® in ex-U.S. markets, VARIZIG® sales in the U.S., and growth in the Distribution segment.

The company also explains its use of non-IFRS measures such as EBITDA and adjusted EBITDA to evaluate operational performance and to compare results over time. These measures are presented alongside IFRS results in its financial communications and SEC filings.

Research, clinical programs and post-marketing studies

In addition to its development-stage work on inhaled AAT, Kamada supports post-marketing research on its marketed products. For CYTOGAM®, the company has announced a comprehensive post-marketing research program and an investigator-initiated clinical trial known as the SHIELD study. This randomized, controlled, multicenter study in high-risk kidney transplant recipients is intended to evaluate the role of CYTOGAM administered at the conclusion of antiviral prophylaxis to reduce the risk of clinically significant late CMV infection.

These activities reflect Kamada’s stated intention to leverage its manufacturing and R&D expertise to generate additional clinical data, refine product use, and advance new product candidates in areas of unmet medical need.

Regulatory and public company status

Kamada files reports as a foreign private issuer under the Securities Exchange Act of 1934. The company submits Form 6-K current reports, which often include press releases, financial statements, and presentations, and notes that certain 6-K filings are incorporated by reference into its Form S-8 registration statements. The presence of recent 6-K filings that attach financial results, tender announcements, clinical updates and other corporate information indicates that Kamada continues to operate as an active, publicly traded company.

Position within the pharmaceutical manufacturing sector

Within the broader pharmaceutical preparation manufacturing sector, Kamada’s disclosures emphasize its focus on specialty plasma-derived products, rare and serious conditions, and a combination of proprietary and in-licensed products. Its integrated model—spanning plasma collection, manufacturing, distribution, and clinical and post-marketing research—defines its role as a specialized biopharmaceutical manufacturer rather than a general pharmaceutical producer.